This treatment enhanced insulin resistance by inhibiting the NF-κB/NLRP3 activation pathway, thereby altering the levels of gut flora metabolites 4-hydroxyphenylacetic acid and 3- (4-hydroxyphenyl) propionic acid (Yao et al., 2022). This evidence concerns the gene NFKB1 and Insulin resistance.